Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium
- PMID: 8545600
- DOI: 10.3109/00365519509104981
Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium
Abstract
The interference of the non-ionic magnetic resonance contrast medium gadodiamide injection (OMNISCAN, Nycomed Imaging, Oslo, Norway) in the colorimetric determination of serum calcium has been investigated in commercial reconstituted serum, and in serum from rabbits and humans dosed with the contrast medium. Inductively coupled plasma-atomic emission spectroscopy (ICP-AES) and ion-selective electrodes were used as reference methods for analysis of serum calcium. The results showed that the colorimetric reagent kit gave an apparent decrease in serum calcium after administration of a clinical dose of gadodiamide injection, and that the extent of interference is correlated to the concentration of the contrast medium. However, serum calcium was not changed when measured by means of an ion-selective electrode or ICP-AES. It is therefore recommended that colorimetric reagent kits should not be used for determination of serum calcium in samples taken within the first 24 h after administration of gadodiamide injection.
Similar articles
-
Acute hemodynamic effects of nonionic and ionic magnetic resonance contrast media in intravenous bolus injection in rats.Invest Radiol. 1994 Jun;29 Suppl 2:S189-91. doi: 10.1097/00004424-199406001-00062. Invest Radiol. 1994. PMID: 7928226 No abstract available.
-
[Use of Omniscan (gadodiamide) in magnetic resonance studies of the central nervous system (results of a multicenter study)].Vestn Rentgenol Radiol. 1995 Jul-Aug;(4):5-11. Vestn Rentgenol Radiol. 1995. PMID: 8571538 Clinical Trial. Russian.
-
In vivo stability and excretion of gadodiamide (GdDTPA-BMA), a hydrophilic gadolinium complex used as a contrast enhancing agent for magnetic resonance imaging.Eur J Drug Metab Pharmacokinet. 1995 Oct-Dec;20(4):307-13. doi: 10.1007/BF03190250. Eur J Drug Metab Pharmacokinet. 1995. PMID: 8983938
-
Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.Invest Radiol. 1993 Mar;28 Suppl 1:S28-43. doi: 10.1097/00004424-199303001-00004. Invest Radiol. 1993. PMID: 8486501 Review.
-
Clinical use of contrast media in magnetic resonance imaging.Br J Hosp Med. 1990 Feb;43(2):149-52. Br J Hosp Med. 1990. PMID: 2178714 Review.
Cited by
-
Interference of medical contrast media on laboratory testing.Biochem Med (Zagreb). 2014 Feb 15;24(1):80-8. doi: 10.11613/BM.2014.010. eCollection 2014. Biochem Med (Zagreb). 2014. PMID: 24627717 Free PMC article. Review.
-
Spurious hypocalcemia after gadodiamide-enhanced magnetic resonance imaging: a case report and review of the literature.Rev Urol. 2006 Summer;8(3):165-8. Rev Urol. 2006. PMID: 17043710 Free PMC article.
-
Analytical Interference by Contrast Agents in Biochemical Assays.Contrast Media Mol Imaging. 2017 Apr 10;2017:1323802. doi: 10.1155/2017/1323802. eCollection 2017. Contrast Media Mol Imaging. 2017. PMID: 29097910 Free PMC article.
-
Contrast media: interactions with other drugs and clinical tests.Eur Radiol. 2005 Jul;15(7):1463-8. doi: 10.1007/s00330-004-2600-1. Epub 2005 Jan 26. Eur Radiol. 2005. PMID: 15968520 Review.
-
[Contrast agents in MRT. Substance, effects, pharmacology and validity].Radiologe. 2004 Mar;44(3):273-83. doi: 10.1007/s00117-004-1026-8. Radiologe. 2004. PMID: 15287365 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources